Literature DB >> 27161823

TORC2 Structure and Function.

Christl Gaubitz1, Manoel Prouteau1, Beata Kusmider1, Robbie Loewith2.   

Abstract

The target of rapamycin (TOR) kinase functions in two multiprotein complexes, TORC1 and TORC2. Although both complexes are evolutionarily conserved, only TORC1 is acutely inhibited by rapamycin. Consequently, only TORC1 signaling is relatively well understood; and, at present, only mammalian TORC1 is a validated drug target, pursued in immunosuppression and oncology. However, the knowledge void surrounding TORC2 is dissipating. Acute inhibition of TORC2 with small molecules is now possible and structural studies of both TORC1 and TORC2 have recently been reported. Here we review these recent advances as well as observations made from tissue-specific mTORC2 knockout mice. Together these studies help define TORC2 structure-function relationships and suggest that mammalian TORC2 may one day also become a bona fide clinical target.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  cancer; conditional knockout mouse model; cryo-electron microscopy; membrane tension homeostasis; metabolism; subunit conservation; subunit topology; target of rapamycin complex 2 (TORC2); therapeutic potential

Mesh:

Substances:

Year:  2016        PMID: 27161823     DOI: 10.1016/j.tibs.2016.04.001

Source DB:  PubMed          Journal:  Trends Biochem Sci        ISSN: 0968-0004            Impact factor:   13.807


  80 in total

Review 1.  The "other" mTOR complex: New insights into mTORC2 immunobiology and their implications.

Authors:  Helong Dai; Angus W Thomson
Journal:  Am J Transplant       Date:  2019-03-19       Impact factor: 8.086

2.  Rapamycin inhibits mTOR/p70S6K activation in CA3 region of the hippocampus of the rat and impairs long term memory.

Authors:  D Lana; J Di Russo; T Mello; G L Wenk; M G Giovannini
Journal:  Neurobiol Learn Mem       Date:  2016-11-10       Impact factor: 2.877

3.  Spatially distinct pools of TORC1 balance protein homeostasis.

Authors:  Vikramjit Lahiri; Daniel J Klionsky
Journal:  Autophagy       Date:  2019-02-06       Impact factor: 16.016

4.  Lateral plasma membrane compartmentalization links protein function and turnover.

Authors:  Jon V Busto; Annegret Elting; Daniel Haase; Felix Spira; Julian Kuhlman; Marco Schäfer-Herte; Roland Wedlich-Söldner
Journal:  EMBO J       Date:  2018-07-05       Impact factor: 11.598

5.  Phosphorylation at distinct subcellular locations underlies specificity in mTORC2-mediated activation of SGK1 and Akt.

Authors:  Catherine E Gleason; Juan A Oses-Prieto; Kathy H Li; Bidisha Saha; Gavin Situ; Alma L Burlingame; David Pearce
Journal:  J Cell Sci       Date:  2019-04-09       Impact factor: 5.285

6.  Metformin Plus Caloric Restriction Show Anti-epileptic Effects Mediated by mTOR Pathway Inhibition.

Authors:  María Del Carmen Rubio Osornio; Verónica Custodio Ramírez; Daniela Calderón Gámez; Carlos Paz Tres; Karla G Carvajal Aguilera; Bryan V Phillips Farfán
Journal:  Cell Mol Neurobiol       Date:  2018-08-21       Impact factor: 5.046

7.  Mammalian target of rapamycin complex 2 (mTORC2) controls glycolytic gene expression by regulating Histone H3 Lysine 56 acetylation.

Authors:  Raghavendra Vadla; Devyani Haldar
Journal:  Cell Cycle       Date:  2018-01-08       Impact factor: 4.534

Review 8.  Caspase involvement in autophagy.

Authors:  Panagiotis Tsapras; Ioannis P Nezis
Journal:  Cell Death Differ       Date:  2017-06-02       Impact factor: 15.828

9.  mTORC2 Responds to Glutamine Catabolite Levels to Modulate the Hexosamine Biosynthesis Enzyme GFAT1.

Authors:  Joseph G Moloughney; Peter K Kim; Nicole M Vega-Cotto; Chang-Chih Wu; Sisi Zhang; Matthew Adlam; Thomas Lynch; Po-Chien Chou; Joshua D Rabinowitz; Guy Werlen; Estela Jacinto
Journal:  Mol Cell       Date:  2016-08-25       Impact factor: 17.970

10.  mTOR Inhibitor Everolimus in Regulatory T Cell Expansion for Clinical Application in Transplantation.

Authors:  Roberto Gedaly; Felice De Stefano; Lilia Turcios; Marita Hill; Giovanna Hidalgo; Mihail I Mitov; Michael C Alstott; D Allan Butterfield; Hunter C Mitchell; Jeremy Hart; Ahmad Al-Attar; Chester D Jennings; Francesc Marti
Journal:  Transplantation       Date:  2019-04       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.